Alumis Inc. (ALMS) vs Monte Rosa Therapeutics, Inc. (GLUE)
A side-by-side comparison of Alumis Inc. and Monte Rosa Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALMS
Alumis Inc.
$6.84HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
GLUE
Monte Rosa Therapeutics, Inc.
$10.27HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — ALMS vs GLUE
growth of $100 · dividends reinvested · last 2yALMS -48.6% (-28.3%/yr)GLUE +203.8% (+74.3%/yr)GLUE compounded faster over this window
Log scale — wide-divergence pair
ALMS GLUE
ALMS vs GLUE: by the numbers
- •GLUE is the larger company ($868M vs $844M market cap).
- •Both run net losses; GLUE's is the smaller (-560.85% vs -5933.45% net margin).
Metrics side by side
Valuation
| Metric | ALMS | GLUE |
|---|---|---|
| P/S ratio | 114.12 | 30.20 |
| P/B ratio | 1.87 | 1.78 |
Profitability
| Metric | ALMS | GLUE |
|---|---|---|
| Gross margin | 88.23% | 92.94% |
| Operating margin | -1776.32% | -43.83% |
| Net margin | -5933.45% | -560.85% |
| ROE | -97.08% | -33.06% |
| ROIC | -94.76% | -28.69% |
Growth (annualized)
| Metric | ALMS | GLUE |
|---|---|---|
| Total return CAGR (5Y) | N/A | -12.32% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.